Notice Regarding Announcement by Partner Steminent Biotherapeutics Inc. of Phase II Clinical Trial Results in Taiwan for Spinocerebellar Ataxia Treatment “Stemchymal®”

Corporate News

YOKOHAMA, Japan – April 25, 2025 – REPROCELL Inc. today announced that its partner, Steminent Biotherapeutics Inc. (Headquarters: Taiwan; hereinafter “Steminent”), reported positive results on April 24, 2025, from Phase II clinical trials conducted in Taiwan and Japan for the stem cell therapy “Stemchymal®” (hereinafter “Stemchymal”). REPROCELL holds the exclusive commercialization license agreement for Stemchymal in…

2nd Global Biologics India 2025

Upcoming Events

📅 Date: 16-17 April 2025 📍 Venue: Hotel Le Meridien, Hyderabad, India Join us at 2nd Global Biologics India 2025, a premier conference bringing together leading experts, researchers, and industry pioneers in Cell and Gene Therapy (CGT), mAbs, and Biosimilars. This two-day event will feature insightful keynote speeches, panel discussions, and networking opportunities with top…

Oligosynthesis

Custom DNA Oligonucleotide Synthesis Services: Precision Tools for Molecular Success

Blogs

Custom DNA Oligonucleotide Synthesis Services: Precision Tools for Molecular Success In modern molecular biology, custom DNA oligonucleotides (or “oligos”) are indispensable tools used in diagnostics, gene editing, synthetic biology, and research. As the demand for personalized, high-quality DNA sequences grows, so does the need for reliable custom oligo synthesis services tailored to specific experimental needs.…